Skip to search formSkip to main contentSkip to account menu

rociletinib

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
ABSTRACT Introduction: Significant advances have been made since the development of epidermal growth factor receptor tyrosine… 
2016
2016
9001Background: Rociletinib is an oral inhibitor of mutant EGFR, including T790M. We compared EGFR mutation detection in… 
2016
2016
9045Background: Rociletinib is an oral, irreversible tyrosine kinase inhibitor of mutant epidermal growth factor receptor… 
Review
2016
Review
2016
ABSTRACT Introduction: Major advances have been made since the discovery of driver mutations and their targeted therapies… 
Highly Cited
2015
Highly Cited
2015
8001 Background: Rociletinib is an oral inhibitor of mutant EGFR, including the T790M resistance mutation. We reported robust… 
2015
2015
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Rociletinib (CO-1686) is a novel, oral…